Brokerages Set Pulmonx Co. (NASDAQ:LUNG) PT at $15.83

Shares of Pulmonx Co. (NASDAQ:LUNGGet Free Report) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $15.83.

A number of brokerages have recently commented on LUNG. Stifel Nicolaus upped their price target on Pulmonx from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $14.00 target price (down from $16.00) on shares of Pulmonx in a research note on Friday, February 23rd. Piper Sandler reissued an “overweight” rating and set a $17.00 price target on shares of Pulmonx in a research note on Wednesday, April 3rd. Finally, Citigroup boosted their price objective on shares of Pulmonx from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, February 23rd.

Get Our Latest Analysis on Pulmonx

Pulmonx Price Performance

NASDAQ:LUNG opened at $7.89 on Friday. The business’s 50-day moving average price is $10.46 and its 200 day moving average price is $10.90. The firm has a market cap of $304.08 million, a P/E ratio of -4.93 and a beta of 0.60. Pulmonx has a 52-week low of $7.72 and a 52-week high of $14.84. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30.

Pulmonx (NASDAQ:LUNGGet Free Report) last released its earnings results on Wednesday, February 21st. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.02. Pulmonx had a negative return on equity of 46.63% and a negative net margin of 88.60%. The company had revenue of $19.30 million for the quarter, compared to analysts’ expectations of $18.24 million. During the same quarter in the previous year, the business posted ($0.38) EPS. The business’s revenue for the quarter was up 25.3% on a year-over-year basis. As a group, sell-side analysts predict that Pulmonx will post -1.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Geoffrey Beran Rose sold 3,097 shares of Pulmonx stock in a transaction on Friday, March 1st. The shares were sold at an average price of $9.06, for a total value of $28,058.82. Following the completion of the sale, the insider now owns 239,952 shares in the company, valued at approximately $2,173,965.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Geoffrey Beran Rose sold 3,097 shares of Pulmonx stock in a transaction on Friday, March 1st. The stock was sold at an average price of $9.06, for a total transaction of $28,058.82. Following the sale, the insider now directly owns 239,952 shares in the company, valued at approximately $2,173,965.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Glendon E. French III sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $12.77, for a total value of $127,700.00. Following the sale, the chief executive officer now owns 1,141,344 shares in the company, valued at $14,574,962.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 49,032 shares of company stock worth $603,390. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Pulmonx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LUNG. Barclays PLC raised its position in shares of Pulmonx by 132.7% in the 3rd quarter. Barclays PLC now owns 92,938 shares of the company’s stock worth $960,000 after purchasing an additional 53,001 shares during the last quarter. FMR LLC lifted its holdings in Pulmonx by 24.7% in the 3rd quarter. FMR LLC now owns 2,029,835 shares of the company’s stock worth $20,968,000 after purchasing an additional 401,830 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Pulmonx during the 3rd quarter worth approximately $3,846,000. Trexquant Investment LP purchased a new stake in shares of Pulmonx during the 3rd quarter worth approximately $368,000. Finally, Aigen Investment Management LP bought a new position in shares of Pulmonx during the 3rd quarter valued at approximately $111,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

(Get Free Report

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Read More

Analyst Recommendations for Pulmonx (NASDAQ:LUNG)

Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.